The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on June 20, 2025

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced …

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo …

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse L’approbation est basée sur des résultats pivots montrant des améliorations de la rémission durable de la maladie et une …

HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support

HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support

BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight management and long-term wellness through a suite of integrated …

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service